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Introduction
　Soluble IL-2R (sIL-2R) is a circulating form of interleu-
kin-2 receptor (IL-2R) released from IL-2R-bearing malig-
nant and normal cells.1), 2)  IL-2R essentially exists in cell 
membranes and serves to functionally trigger active signals. 
This membrane form consists of three different subunits: 
alpha, beta and gamma. The alpha unit (CD25) was first 
identified on adult T-cell leukemia (ATL) as Tac antigens.3) 
Since serum sIL-2Rs are substantially overproduced in IL-
2R-bearing tumor cells, sIL-2R is used as a surrogate bio-
marker for assessing the extent of a tumor.4), 5)
　Interleukin-2 (IL-2) is stimulated mainly by IL-1 and 
IL-6 via activated mono-macrophages and leads to activa-
tion of T-cell immunity, which consequently increases sIL-
2R. Thus, serum sIL-2R can similarly be expected to act as 
a marker for evaluating occult or aberrant immunity.
　Atypical lymphocytes were originally defined according 
to morphologic characteristics, showing an abundant and 
basophilic cytoplasm with aberrant chromatin and nucleoli. 
Similarly to sIL-2R, the appearance of atypical lympho-
cytes in peripheral blood is considered to indicate active 
immune status.6) This phenomena frequently occur with vi-
ral infections in children, such as herpes simplex virus, 
Epstein-Barr virus (EBV), Coxsackie virus, cytomegalovi-
rus and hepatitis A virus (HAV). Furthermore, atypical 
lymphocytes have been observed in the peripheral blood of 
patients in a large number of clinical situations, including 
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graft-versus-host disease in transplantation, collagen dis-
eases, autoimmune disorders, malignant tumors, and drug 
reactions. Since atypical lymphocytes can potentially pro-
duce various cytokines, it is important to monitor risk for 
severe conditions caused by cytokine storms. However, the 
measurement of atypical lymphocytes in an automated 
complete bood count (CBC) analyzer, which is the most 
standard device used in hospitals, is often substantially 
inaccurate. Therefore, we were interested in examining 
whether serum sIL-2R levels could surrogate the laboratory 
role of atypical lymphocytes. Data analysis was performed 
using the method of Principal Component Analysis (PCA), 
a data projection method which can be helpful in classifica-
tion.7) The central idea of PCA is to reduce the dimensional-
ity (number of variables) of a data set but retain most of the 
original variability in the data.8),9) It computes a few linear 
combinations of the original variables, which can be used to 
summarize the data with minimal loss of information.10)
Subjects and study design
　Serum IL-2R levels were measured in a total of 847 blood 
samples from in- and out-patients as a test mainly for evalu-
ation of malignancy at Nagasaki Harbor Medical Center 
City Hospital during the period from April to October 2013. 
The levels were determined by a chemiluminescent enzyme 
immunoassay (CLEIA) (Siemens Healthcare Diagnostics, 
Tokyo, Japan), of which the normal range in adults is 152 to 
492 U/ml. For samples in which the atypical lymphocyte 
data as measured by the CBC auto-analyzer Sysmex XE-
5000 (Sysmex Corporation, Kobe, Japan) appeared to be 
incorrect, the samples were flagged for re-evaluating atypi-
cal lymphocyte levels by means of microscopic manual 
examination.  As per standard procedure, all samples from 
patients of Pediatric department were evaluated by micro-
scopic manual examination. Other data included in our anal-
ysis were white blood cell (WBC) count, neutrophil (Neu) 
count, Neu percentage, lymphocyte (Ly) count, Ly percent-
age, platelet (Plt) count, hemoglobin (Hb) level, alanine 
aminotransferase (ALT) level, lactate dehydrogenase level 
(LDH) and serum high-sensitive C-reactive protein (hs-
CRP) level. All clinical data were collected from practical 
examination and saved in the hospital computer system. Sur-
face markers of lymphocytes were not evaluated and the 
transition of parameters in the each patients were not vali-
dated in this study. 
Statistical analysis
　The Kruskal-Wallis test and the Spearmanʼs rank correla-
tion coefficient test were applied according to the distribu-
tion of data. The results were judged by the p-value (signifi-
cant: < 0.05) and by the boundary value. Correlations of 
parameters were subjected to Principal Component Analysis 
(PCA) with Microsoft Excel and add-in software. 
Results
1. Serum sIL-2R levels were usually high in patients with 
atypical lymphocytes.
　Serum sIL-2R was detectable in all samples, varying from 
122 to 301150 U/mL, thus showing inter-sample variation 
(Figure 1).  Atypical lymphocytes (atyLy) were microscopi-
cally identified in 30 patients, including 5 adults with 5% 
atyLy or more per leukocyte fraction. 25 of the 30 patients 
were patients of Pediatric department (mean age = 8.4 years, 
male to female ratio = 0.93). The total serum sIL-2R levels 
of the pediatric patients were distributed from 200 to 3159 
U/mL, as indicated by stars (*) on Figure 1. 4 cases were 
respectively diagnosed as Adeno virus infection, EB-virus 
infection, Bartonella infection and familial Mediterranean 
fever. The chief complaints of other undiagnosed patients 
were as follows: lymphadenopathy; 7 cases, fever with skin 
rashes; 3 cases, joint pain; 3 cases, fever alone; 2 cases, skin 
rushes alone; 1 case, abdominal pain; 1case, general mal-
aise; 1case, listlessness; 1 case, liver disorder; 1 case, fever 
with neck pain; 1case. The 25 pediatric patients were classi-
fied into three groups according to atyLy/Lymphocyte ratio 
(Class 1: atyLy/Ly of less than 5%, Class 2: 6-49%, Class 3: 
50% or more), as summarized in Table 1. In evaluating these 
3 groups using the Kruskal-Wallis test, sIL-2R was the pa-
rameter which correlated the most closely with the atyLy/Ly 
ratio (p=3.67e-5<0.05), although LDH (p=0.0166), hs-CRP 
(p=0.0003) and WBC (p=0.0045) also showed significant 
correlation with the atyLy/Ly ratio. 
2. Correlation and Principal Component Analysis (PCA; a 
technique for data analysis and processing)
　To identify a factor correlating with atyLy/Ly features, we 
subjected the data of 25 patients to Spearman's rank correla-
tion coefficient test and to PCA. The closest correlation was 
observed between sIL-2R and atyLy/Ly (Spearman rank cor-
relation coefficient = 0.92, p=6.23e-6 <0.05). Figure 2 shows 
that the atyLy/Ly ratio rose from Class 1 (<5%) to Class 2 
(6-49%) across serum sIL-2R levels of 366 to 397 U/ml, and 
that the atyLy/Ly ratio rose from Class 2 to Class 3 (above 
59Kazuhisa Nakashima et al.: Soluble IL-2 Receptor and Atypical Lymphocytosis
50%) across serum sIL-2R levels 799 to 809 U/m. Serum 
LDH levels (rs=0.57, p=0.006<0.05), hs-CRP (rs=0.79, 
p=0.0001<0.05) and WBC (rs=0.62, p=0.0022<0.05) were 
also correlated with atyLy/Ly. However, sIL-2R was more 
useful for presuming the atyLy/Ly ratio than the other pa-
rameters, as clearly illustrated in Figure 2 by the compara-
tively very low overlap between AtyLy/Ly class distributions.
　Next we performed Principal Component Analysis to 
clarify the relationship between parameters. The results of 
the PCA are shown in Table 2. The first component increased 
proportionally with the parameters sIL-2R, LDH, WBC, Ly 
count, Ly percentile and atyLy/Ly. The first component (con-
tribution ratio (CR) was 0.384) was considered to mainly 
reflect the extent of lymphocyte activity. Similarly, the sec-
ond component (CR: 0.258) as represented by Neu count, 
Neu percentage and hs-CRP was considered to reflect neu-
trophil-related inflammation. The third component (CR: 
0.137) might reflect liver disorders related to ALT and LDH. 
The cumulative contribution ratio of the first, second and 
third components was 0.779.
Discussion
　Atypical lymphocytes are readily identified by their in-
creased size and the presence of active DNA synthesis. They 
are considered to be the activated form of lymphocytes. 6)  At 
present, while experimental and clinical analyses of lympho-
cytes are mainly performed by surface markers or cytokines, 
morphological assessment of atypical lymphocytes in pe-
ripheral blood continues to be essential for evaluating active 
lymphocytes in vivo.
　Although hematology analyzers continue to improve in 
performance year by year, their ability to classify differing 
leukocytes remains limited. Sensitivity is especially poor in 
distinguishing the morphological variations between normal 
lymphocytes, abnormal lymphocytes, lymphoblasts, and 
atypical lymphocytes. For example, sensitivity was reported 
as 51.2% in an efficient analyzer Sysmex XE-5000. 11) With 
respect to the flagged blood samples from the analyzer in our 
study, twice as many samples were identified as containing 
atypical lymphocytes when observed by manual review than 
when measured by the analyzer alone. In other words, on the 
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lymphocytes were overlooked. Therefore, given that the 
AtyLy/Ly ratio was comparatively high at serum sIL-2R lev-
els of about 400 U/ml and exceeded 50% at serum sIL-2R 
levels of 1000 U/ml or more, the ratioʼs close correlation 
with serum sIL-2R levels is especially of interest.  Though 
we could not find any reports directly describing the rela-
tionship between sIL-2R and atypical lymphocytosis, a se-
rum sIL-2R level appears to be applicable as a detective 
marker for assessing lymphocyte transformation in periph-
eral blood—similar to its marker role against cancer-derived 
lymphoid cells. Serum sIL-2R data may therefore prove 
complementary of automated hematology analyzer data, 
thereby offsetting analyzer-related inaccuracies in identify-
ing atypical lymphoid cells.  Serum sIL-2R is currently rec-
ognized as a marker of many cancers, of collagen disease, 
and of viral infections.1), 5),12-15) Serum sIL-2R may therefore 
additionally prove applicable in treating most diseases as a 
universal marker, considering that most diseases are sub-
stantially accompanied with activation of lymphocytes.
Conclusion
　Serum sIL-2R is useful to detect atypical lymphocytosis 
resulting from lymphoid cell activation. A serum sIL-2R 
level of approximately 400 U/ml suggests the possibility of 
detecting atypical lymphocytes. A serum sIL-2R level of 
1000 U/ml or more indicates remarkable atypical lymphocy-
tosis. 
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Table 1. Clinical characteristics of the disease status of 3 Groups classified by atypical lymphocyte/total lymphocyte ratio








Number of patients 5 9 11
Male/Female ratio 0.67 1.25 1.75 0.8403
Mean age (years) 13.6 7.6 6.7 0.0561
sIL-2R (U/ml) c 289.8 565.3 1945.3 3.67e-5 <0.05
LDH (IU/L) d 166.4 231.4 306.0 0.0166 <0.05
ALT (IU/L) e 12.0 15.1 47.8 0.0150 <0.05
hs-CRP (mg/dl) f 0.03 0.06 2.56 0.0003 <0.05
Hemoglobin (g/dl) 13.9 13.5 12.7 0.2872
Platelet ( × 104/mm3) 21.5 25.7 35.9 0.0803
WBC (/mm3) g 6920 6644 11218 0.0045 <0.05
Neutrophil (%) 59.8 48.2 52.9 0.4283
Neutrophil (/mm3) 4280 3318 5791 0.0771
Lymphoyte (%) 30.6 38.6 38.4 0.4999
Lymphocyte (/mm3) 2034 2480 4503 0.1564
a p-value: p-value of Kruskal-Wallis test 
b atyLy/Ly: atypical lymphocyte/total lymphocyte ratio
c sIL-2R: soluble IL-2 receptor
d LDH：lactate dehydrogenase
e ALT: alanine aminotransferase
f hs-CRP: high-sensitive C-reactive protein 
g WBC: white blood cell













































Figure 2. Correlation of parameters and atypical lymphocyte/lymphocyte ratio (atyLy/Ly) 
AtyLy/Ly was classified into 3 classes: Class 1; less than 5%, Class 2; 6-49%, Class 3; 50% or more. 
sIL-2R was the parameter most closely correlated with atyLy/Ly and was useful to presume atyLy/Ly.  
Figure 2.  Correlation of parameters and atypical lymphocyte/lymphocyte ratio (atyLy/Ly)
Table 2. Principal Component Analysis of laboratory parameters
Components
1 2 3
AtyLy/Ly a 0.826 0.331 0.248
sIL-2R (U/ml) b 0.685 0.322 0.231
LDH (IU/L) c 0.671 -0.158 0.623
ALT (IU/L) d 0.467 -0.286 0.727
hs-CRP (mg/dl) e 0.215 0.593 0.020
Hemoglobin (g/dl) -0.595 -0.232 0.491
Platelet ( × 104/mm3) 0.715 0.218 -0.468
WBC (/mm3) f 0.700 0.498 -0.100
Neutrophil (%) -0.524 0.802 0.162
Neutrophil (/mm3) 0.038 0.932 0.063
Lymphoyte (%) 0.626 -0.712 -0.225
Lymphocyte (/mm3) 0.851 -0.227 -0.242
Contribution ratio 0.384 0.258 0.137
a atyLy/Ly: atypical lymphocyte/total lymphocyte ratio
b sIL-2R: soluble IL-2 receptor
c LDH：lactate dehydrogenase
d ALT: alanine aminotransferase
e hs-CRP: high-sensitive C-reactive protein
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